全球人造血液市场（~2028）

全球人造血液市场规模预计将从 2022 年的 2390 万美元和 2023 年的 2610 万美元增长到 2028 年的 4050 万美元，预测期内年复合成长率为 9.2%。

本报告调查了全球人造血液市场，并提供了市场概况、市场影响因素和市场机会分析、市场规模趋势和预测、各个细分市场和地区的详细分析、产品分析以及技术和专利趋势、竞争形势、概况主要企业等

目录

第1章简介

第2章总结/要点

第3章市场概况

• 人类血液问题
• 人造血液的新需求
• 人造血液：有助于解决感染疾病风险
• 人造血液：减轻献血者血液供应负担
• 人造血液：需要应对血液系统的意外需求
• 开发人造血液製品的障碍
• 人造血液的理想特性
• 人造血液优于人类血液
• 用途
• 外科手术
• 紧急復苏
• 短期使用
• 案例比人血更有效
• 因宗教信仰而拒绝
• 人造血液开发的课题

第4章市场动态

• 促进因素
• 输血需求增加
• 与输血相关的风险和课题
• 血液供应不足
• 障碍
• 产品核可率低
• 产品验收
• 产品定价
• 机会
• COVID-19 的影响

第5章人造血液：按来源分类

• 人造血液是由人类血液研製而成
• 由动物血液研製而成的人造血液
• 利用基因重组技术开发的人造血液
• 表面修饰血红蛋白
• 交联血红蛋白
• 聚合血红蛋白
• 封装
• 基因工程重组血红蛋白
• 天然血红蛋白

第6章人造血液：按类型

• 全氟化碳乳液
• 全氟化碳的一般性质
• 乳液选择
• 全氟化碳乳液的历史发展
• 第一代PFC
• 第二代PFC
• 第三代PFC
• 血红蛋白氧载体 (HBOC)
• HBOC的一般特征
• 历史事件：血红蛋白溶液

第7章市场预估

• 人造血液的潜在市场
• 人造血液市场：按来源分类
• 血液（动物/人）
• 合成聚合物
• 人造血液市场：按类型
• 血红蛋白氧载体
• 全氟化碳产品
• 人造血液市场：按地区
• 北美
• 欧洲
• 新兴市场

第8章新技术和发展

• 概述
• 新技术
• 纳米胶囊技术
• 干细胞
• 其他正在进行的血液替代品研究

第9章产品分析

• 产品安全
• 产品功效
• 产品成本
• 法律影响
• 部分在研产品的产品分析
• Hemopure
• HemO2life
• HemoTech
• NanO2 (DDFPe)
• Sanguinate
• Vidaphor
• 临床试验
• 一些处于临床前和早期 I 期阶段的产品的描述
• ErythroMer
• Hemoglobin vesicles
• OxyVita
• OxyBridge

第10章专利分析

• FDA法规
• FDA 良好生产规范和报告
• 专利分析

第11章竞争资讯

• 战略发展
• 竞争分析

第12章公司简介

• AURUM BIOSCIENCES
• ERYPHARM
• HEMOGLOBIN OXYGEN THERAPEUTICS LLC.
• HEMARINA
• KALOCYTE INC.
• NANO SANGUIS SA
• NUVOX PHARMA LLC.
• PROLONG PHARMACEUTICALS, LLC
• RED C BIOTECH
• VIRTECH BIO

Highlights:

The global artificial blood market reached $23.9 million in 2022, should reach $26.1 million by 2023 and $40.5 million by 2028 with a compound annual growth rate (CAGR) of 9.2% during the forecast period of 2023-2028.

Report Scope:

The scope of this study encompasses an investigation of the global market for artificial blood, focusing on various important aspects of the market, such as research and development, clinical trial outcomes, approval status, and the potential commercial demand for artificial blood products. The report includes a discussion of artificial oxygen carrier products. BCC Research analyzes each market segment and provides a forecast for six years. The current report analyzes the market's drivers, challenges, and opportunities. The report also covers market projections for 2028 and the market analysis for key market players. The report includes the company profiles of the key players with detailed information about their business segments, financials, product portfolios, and recent developments. The report also provides information on emerging technologies, the impact of COVID-19, product analysis, deals, and investment outlook.

Report Includes:

• 41 tables
• An overview of the global markets for artificial blood
• Estimation of market size and analyses of global market trends, with data from 2020-2022, estimates for 2023, and projections of compound annual growth rates (CAGRs) through 2028
• Highlights of the market potential and characterization of artificial blood market by product, application, and region
• Examination of the key drivers and constraints that will shape the market and discussion on the upcoming market opportunities and areas of focus to forecast the market into various segments and sub-segments
• Coverage of recent advances, emerging technologies, and developments of the industry
• Evaluation of key industry acquisitions and strategic alliances and market share analysis of the leading suppliers of the industry
• Company profiles of major players within the industry, including Hemarina, VirTechBio, and NuvOx Pharma

Table of Contents

Chapter 1 Introduction

• Study Goals and Objectives
• Reasons for Doing This Study
• Scope of Report
• What's New in This Update?
• Methodology
• Information Sources
• Geographic Breakdown

Chapter 2 Summary and Highlights

• Market Overview

Chapter 3 Market Overview

• Introduction
• Is There a Problem with Human Blood?
• Emerging Needs for Artificial Blood
• Artificial Blood Will Be Useful in Dealing with the Risks of Infection
• Artificial Blood Will Help to Decrease the Load on the Donor Blood Supply
• Artificial Blood Is Needed to Deal with Unexpected Demands on the Blood System
• Hurdles in the Development of Artificial Blood Products
• Ideal Characteristics of Artificial Blood
• Artificial Blood Over Human Blood
• Applications
• Surgeries
• Emergency Resuscitation
• For Short-term Use
• Where More Effective Than Human Blood
• Rejections Due to Religious Beliefs
• Challenges in Artificial Blood Development

Chapter 4 Market Dynamics

• Drivers
• Increasing Demand for Blood Transfusions
• Risks and Challenges Associated with Blood Transfusions
• Shortage of Blood Supply
• Barriers
• Low Rate of Product Approvals
• Product Acceptance
• Product Pricing
• Opportunities
• Impact of COVID-19

Chapter 5 Artificial Blood by Source

• Introduction
• Artificial Blood Developed from Human Blood
• Artificial Blood Developed from Animal Blood
• Artificial Blood Developed Using Recombinant Technology
• Surface Modified Hemoglobin
• Cross-Linked Hemoglobin
• Polymerized Hemoglobin
• Encapsulation
• Genetically Engineered Recombinant Hemoglobin
• Natural Hemoglobin

Chapter 6 Artificial Blood by Type

• Introduction
• Perfluorocarbon Emulsions
• General Characteristics of Perfluorocarbons
• Emulsion Selection
• Historical Developments of Perfluorocarbon Emulsions
• First Generation of PFCs
• Second Generation of PFCs
• Third Generation of PFCs
• Hemoglobin-based Oxygen Carriers
• General Characteristics of HBOCs
• Historical Events: Hemoglobin Solutions

Chapter 7 Market Estimation

• Introduction
• Potential Market for Artificial Blood
• Artificial Blood Market, by Source
• Blood (Animal/Human)
• Synthetic Polymers
• Artificial Blood Market, by Type
• Hemoglobin-based Oxygen Carriers
• Perfluorocarbon-based Products
• Artificial Blood Market, by Region
• North America
• Europe
• Emerging Markets

Chapter 8 Emerging Technologies and Developments

• Overview
• Emerging Technologies
• Nanocapsule Technology
• Stem Cells
• Other Ongoing Research for Blood Substitutes

Chapter 9 Product Analysis

• Introduction
• Product Safety
• Product Effectiveness
• Product Cost
• Legal Implications
• Product Analysis of Some of the Products Under Development
• Hemopure
• HemO2life
• HemoTech
• NanO2 (DDFPe)
• Sanguinate
• Vidaphor
• Clinical Trials
• Product Description of Some of the Products in Preclinical and Early Phase I Stage
• ErythroMer
• Hemoglobin vesicles
• OxyVita
• OxyBridge

Chapter 10 Patent Analysis

• Introduction
• FDA Regulation
• FDA Good Manufacturing Practices and Reporting
• Patent Analysis

Chapter 11 Competitive Intelligence

• Strategic Developments
• Competitive Analysis

Chapter 12 Company Profiles

• AURUM BIOSCIENCES
• ERYPHARM
• HEMOGLOBIN OXYGEN THERAPEUTICS LLC.
• HEMARINA
• KALOCYTE INC.
• NANO SANGUIS S.A
• NUVOX PHARMA LLC.
• PROLONG PHARMACEUTICALS, LLC
• RED C BIOTECH
• VIRTECH BIO

List of Tables

• Summary Table : Global Market for Artificial Blood, Through 2028
• Table 1 : Historical Events Related to Blood Transfusion, 1628-2022
• Table 2 : Potential Benefits and Application Areas of Artificial Blood
• Table 3 : Average Number of Blood Units Required During Particular Medical Conditions
• Table 4 : The Challenges Associated with the Development of Artificial Blood
• Table 5 : Common Challenges to the Blood Transfusion Continuum in LMICs.
• Table 6 : Sources of Hemoglobin Molecules Used to Prepare Free Hemoglobin Solutions
• Table 7 : Pros and Cons of Artificial Blood Developed from Human Blood
• Table 8 : Pros and Cons of Artificial Blood Developed from Animal Blood
• Table 9 : Pros and Cons of Artificial Blood Developed from Recombinant Blood
• Table 10 : Summary of Acellular Hb-Based Oxygen Carriers
• Table 11 : Examples of Hemoglobin-based Oxygen Carrier Products and Approval Status
• Table 12 : Potential Clinical Applications of Oxygen Carriers
• Table 13 : Composition of PFC Emulsion-Based Artificial Blood Products
• Table 14 : First Generation Perfluorocarbon Emulsions Used in Medicine and Biology
• Table 15 : Comparative Study of Second-Generation PFCs
• Table 16 : PFC Emulsion Products and Current Status
• Table 17 : Comparative Study Between RBCs and HBOCs
• Table 18 : HBOC Solutions Transfusion: Side Effects and Possible Causes
• Table 19 : Examples of HBOC Products Developed, by Various Companies
• Table 20 : Global Market for Artificial Blood, Through 2028
• Table 21 : Current Cell Sources and Strategies for Ex-vivo RBC Generation
• Table 22 : List of Discontinued Blood Substitutes
• Table 23 : Hemopure: Raw Material and Method Overview
• Table 24 : Hemopure: Product Characteristics
• Table 25 : Hemopure: Advantages and Disadvantages
• Table 26 : Summary of Clinical Trials of Hemopure (HBOC-201), 2023
• Table 27 : HemO2life: Raw Material and Method
• Table 28 : HemO2life: Advantages and Disadvantages
• Table 29 : HemO2life: Product
• Table 30 : Ex vivo, In vivo and Clinical Studies involving HemO2life (M101) Use
• Table 31 : Hemotech: Raw Material and Method Overview
• Table 32 : HemoTech: Advantages and Disadvantages
• Table 33 : NanO2 (DDFPe): Raw Material and Method Overview
• Table 34 : NanO2 (DDFPe): Advantages and Disadvantages
• Table 35 : NanO2 (DDFPe): Clinical Trials, 2023
• Table 36 : Sanguinate: Raw Material and Method Overview
• Table 37 : Sanguinate: Advantages and Disadvantages
• Table 38 : Sanguinate: Clinical Trials, 2023
• Table 39 : Vidaphor: Raw Material and Method Overview
• Table 40 : Vidaphor: Advantages and Disadvantages
• Table 41 : Vidaphor: Clinical Trials, 2023

List of Figures

• Summary Figure : Global Market for Artificial Blood, 2020-2028
• Figure 1 : The Blood Continuum
• Figure 2 : Medical Use of Human Red Blood Cells in the U.S., 2019
• Figure 3 : Estimated Number of New Cancer Cases from 2020 to 2040
• Figure 4 : Discards of Blood Donations, by Reason, 2018
• Figure 5 : Artificial Blood Manufactured from Different Sources
• Figure 6 : History of HBOCs Developed Using Recombinant Technology
• Figure 7 : Classification of Modified Hemoglobin Solution Based on Methods
• Figure 8 : Classification of Different Types of Oxygen Carriers
• Figure 9 : Generations of Perfluorocarbon Emulsions
• Figure 10 : Advantages and Disadvantages of PFC Emulsions
• Figure 11 : Evolution of HBOCs
• Figure 12 : Advantages and Disadvantages of HBOCs
• Figure 13 : Global Potential Market for Artificial Blood, by Application, 2028
• Figure 14 : Biosynthetic RBC vs Artificial Blood Substitutes
• Figure 15 : Artificial Blood: Parameters for Product Analysis
• Figure 16 : Hemopure: Product Analysis
• Figure 17 : HemO2life: Product Analysis
• Figure 18 : NanO2 (DDFPe): Product Analysis
• Figure 19 : Sanguinate: Product Analysis
• Figure 20 : Current Competition in the Global Artificial Blood Market